- Research Services
- Capabilities
- About Us
- Resources
- Contact Us
Abstract:
For patients with ulcerative colitis, the most common form of inflammatory bowel disease (IBD), aminosalicylates such as mesalamine provide first-line anti-inflammatory therapy. As efficacy is related to tissue concentration, when administered as a rectal enema, lack of retention challenges topical formulation effectiveness. To address this problem, Schoellhammer and his colleagues (Wu et al, 2015) recently described the development and pre-clinical testing of a novel delivery system in which they incorporated low-frequency ultrasound (LFU) as a means to enhance transmucosal drug delivery through the gastrointestinal mucosa.
